Replies to post #104567 on Biotech Values

[jq1234]

Another question is whether the typical melanoma patient will be willing to stay out of the sun while taking PLX4032.

Exllent point. I was shocked after reading this part.

While I consider the article overall good, I am a little bit disturbed by the emotional approach to the subject of clinical trial/drug development process rather than scientific approach. I would like to see two separate articles, one from emotional approach, one from scientific approach - as a couple of other posts pointed out already, much of this drug is still unknown. The article tried to make judgement on clinical trial/drug development process, while tried not to make judgement on individual behavior.

[Biowatch]

Quote:Interesting question is whether the incidence of squamous cell carcinoma [while taking PLX4032] can be avoided just by rigorously avoiding the sun - or is it previous sun damage that is turned into squamous cell carcinoma?

Another question is whether the typical melanoma patient will be willing to stay out of the sun

Unlike many rather benign skin cancers, I was under the impression that melanoma can spring up anywhere, even in places with relatively little exposure to the sun. Or perhaps they are harder to spot until it's too late if they aren't on your face or arms.

[rkrw]

The squamous won't kill them. The melanoma will. What's more interesting to me is what drugs will be combined with PLX to extend the impressive but still relatively modest duration.